Across TCGA pan-cancer cohorts, BPNT2P RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of BPNT2P’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where BPNT2P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types BPNT2P is over-expressed in tumor.
BRCA and LUSC are the cancer types where BPNT2P tumor–normal differential expression is most reproducible.